SynthesisFrontiers in cardiovascular medicine2025
Systematic review of Chinese medicine for the treatment of atherosclerosis.
Synthesis in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanism of Shuangshen Xionglian Granule in Attenuating EndMT in Atherosclerosis via the FGFR1-TGF-β/Smad2 Axis.Molecular nutrition & food research · 2026Article
- Phytochemical Monomers Derived from Traditional Chinese Medicine May Prevent and Treat Atherosclerosis by Modulating the Macrophage Mitochondrial-Lysosomal Senescence Axis.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atherosclerosis (AS) is a chronic inflammatory metabolic disease strongly associated with risk factors, including hypertension, hyperlipidemia, hyperglycemia, and hyperuricemia. AS serves as the pathological foundation for numerous cardiovascular diseases (CVDs), and it remains a major threat to global health. However, the underlying mechanisms driving AS development are incompletely understood. Elucidating the pathogenesis and key influencing factors of AS is critical for identifying novel preventive strategies and therapeutic approaches. Methods: We searched PubMed and Web of Science for relevant studies. We selected relevant English research articles published between 2012 and 2024. Afterward,we analyzed and summarized the pharmacological effects and molecular mechanisms of these Chinese medicines. Results: Through our search and exclusion criteria, a total of 116 preclinical studies and 6 clinical research articles were found. Discussion: Traditional Chinese medicine (TCM), with over 2000 years of clinical application, offers a rich source of potential interventions. Integrating modern medical technologies allows for the reevaluation of TCM from a natural compound perspective. This review comprehensively summarizes the mechanisms by which single herbal medicines (SHMs) and their derived natural compounds (NCs) exert effects against AS on the basis of preclinical evidence and analysis of seven selected double-blind, randomized, placebo-controlled clinical trials (RCTs).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.